


Systems biology of vaccination for seasonal influenza in humans

Nakaya, H., Wrammert, J., Lee, E. *et al.* (2011)

Presented by Team Sydney Brenner
Erica Anton, Annelisa Faché, Ziqing Yu
September 26, 2024



Introduction

RESOURCE



Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans

Troy D Querec^{1,8}, Rama S Akondy^{1,8}, Eva K Lee², Weiping Cao¹, Helder I Nakaya¹, Dirk Teuwen³, Ali Pirani⁴, Kim Gernert⁴, Jiusheng Deng¹, Bruz Marzolf⁵, Kathleen Kennedy⁵, Haiyan Wu⁵, Soumaya Bennouna¹, Herold Oluoch¹, Joseph Miller¹, Ricardo Z Vencio⁵, Mark Mulligan^{1,6}, Alan Aderem⁵, Rafi Ahmed¹ & Bali Pulendran^{1,7}


A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene 'signatures' that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4—an orchestrator of the integrated stress response—that correlated with and predicted YF-17D CD8⁺ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor *TNFRS17*, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.

Systems biology approach has been used for yellow fever vaccine YF-17D

- ❑ The **first time** they used high-throughput technologies combined with computational modeling **in vaccinology**
- ❑ Identify **early gene signatures**
- ❑ **Predicting** the subsequent adaptive immune response

Introduction

Can the signatures identified with YF-17D also be used to predict the immunogenicity of other vaccines ?



Nature Reviews Immunology, volume 9, pages741–747 (2009)

Nature Reviews | Immunology

Hypothesis

- Universal 'archetypal' signature for T and B cell immunogenicity of all vaccines
- Each vaccine had a unique signature
- Classes of vaccines that induce similar signatures of immunogenicity (**most likely**)

Introduction

Influenza vaccine

- trivalent inactivated influenza vaccine (**TIV**)
- live attenuated influenza vaccine (**LAIV**)

The differences from yellow fever vaccine YF-17D

- TIV is inactivated vaccine
- Recall response from prior infections and vaccinations

Comparison of the immune response to inactivated influenza and live attenuated influenza vaccine.


	Inactivated Influenza Vaccine	Live Attenuated Influenza Vaccine
HAI response	+++	+
Antibody secreting cells	++	+
Memory B cells	+	+
Nasal IgA	-/+	+++
NA antibody	-/+	++
CD4 T cells	++	+++
CD8 T cells	-	+
Cross protective immunity	-/+	++



The feasibility of this approach in predicting IFA vaccine's immune response


Introduction

- Antibody response after TIV and LAIV is different





- Molecular signatures of peripheral blood mononuclear cells (PBMCs) after TIV and LAIV is different (Transcriptome analysis)

Signature for immunogenicity of different vaccines could be different




Introduction




- Logistically: need to use freshly isolated samples to prevent the 'preferential' loss of certain cell types
- Financially: the need for large numbers of gene chips

DAMIP (a very powerful supervised-learning classification method for predicting various biomedical and 'biobehavioral' phenomena) + RT-PCR



Why meta-analysis?


- Self-conducted microarray analysis via flow cytometry = **time and resource consuming**
- Meta-analysis:** combining and analysing data from several studies to identify gene-expression patterns
 - Larger sample set**
 - More efficient analysis**
 - Cell-specific results**



Meta-analysis of microarray data


- Publicly available **PBMC microarrays** divided into:
 - T cells, B cells, monocytes, natural killer cells
 - B cell subsets: naive, memory, germinal center, ASCs
- Identified **highly expressed genes** in each subset
- Compared to **microarray data of plasmacytoid and myeloid dendritic cells** post-TIV and LAIV vaccination

Output: early gene signatures from vaccine response



Machine Learning: Background

- Machine Learning (ML) allows systems to learn and improve from data
- ML relies on algorithms to complete a task using data patterns
- Supervised Learning
 - often used for classification algorithms
 - model is trained with a known, labeled dataset
 - using results data from one dataset to classify results of another dataset



DAMIP Machine Learning

- Discriminant Anal^ysis via Mixed Integer Programming
- Supervised ML → the training and testing datasets have known results
- Frequently used for predicting and classifying biological processes

Application:

- Influenza vaccine → determine minimum number of genes required to get an accurate classification of response type
- DAMIP used to be able to predict HAI response to TIV vaccine
- Trained with existing datasets to predict response in other influenza seasons
- Make connections between identified genes and other vaccine responses




Meta-Analysis Results

- TIV
 - genes upregulated are associated with high **B cell expression**
 - genes encode for antibody parts and immunoglobulins
 - results align with flow cytometry results
 - indicate high antibody response in mechanism of action in TIV
- LAIV
 - gene upregulated are associated with high **T cell and monocyte expression**
 - genes encode for natural killer cells
 - results align with flow cytometry results
 - indicate innate response important in mechanism of action in LAIV

DAMIP: Background + Initial Testing

- **Goal: ID minimum number of genes needed to predict HAI response**
- DAMIP
 - supervised learning method for prediction biological phenomena
 - using TIV vaccine responses only




- HAI titers response: measures level of antibodies in serum used to inhibit influenza
 - higher HAI → higher protection from influenza

DAMIP: Initial Testing

- Initial Testing:
 - extreme HAI classification groups
 - very high HAI responders $\geq 8x$ HAI response
 - very low HAI responders $\leq 2x$ HAI response
 - training establishes unbiased estimate of correct classification
 - 2008-2009 influenza season data used for training


DAMIP analysis 1
(eightfold cutoff)



DAMIP: Initial Test Results


- Training Data: 2008-2009 influenza season
- Testing Data: 2007-2008 influenza season
- Results:
 - DAMIP identified **12 gene sets** (each with 2-4 individual genes)

90+% of the low/high HAI response guesses for test data were correct based on learning from training data



DAMIP: Repeat Testing


- Repeat Testing:
 - less extreme HAI classification groups
 - high HAI responders $\geq 4x$ HAI response
 - 4x HAI response is the widely defined seroconversion after vaccination
 - very low HAI responders $\leq 2x$ HAI response
 - 2008-2009 influenza season data used for training



DAMIP: Repeat Test Results


- Training Data: 2008-2009 influenza season
- Testing Data 1: 2007-2008 influenza season
- Testing Data 2: 2009-2010 influenza season
- Results
 - DAMIP identified **42 gene sets** (each with 3-4 individual genes)

85% of the low/high HAI response guesses for test data were correct based on learning from training data



Interesting Finds!

- One of the 42 identified genes (TNFRSF17) in the repeat test also identified with predicting antibody response in YF-17D (Yellow Fever) vaccine
- Five of the 42 identified genes in the repeat test are members of leukocyte immunoglobulin receptor family
 - Expressed by immune cells in myeloid and lymphoid lineages
 - Immunomodulatory roles in innate and adaptive immune system
 - Regulate T cells and autoimmunity
 - **Indicates possibility of innate immune receptors in regulating antibody response**



Discussion: Strengths

- **Meta-analysis** of microarray studies
>>> traditional flow cytometry
- New **insight to molecular mechanism** of vaccine response
 - Immunity with **LAIV vs. TIV**
 - Identified **CaMKIV & LILRs**
- **Machine learning as prediction tool** for immunogenicity of vaccine
 - Predicted TIV with **accuracy >90%**
 - **Predicts seroconversion weeks** before it occurs




Figure 3. Genes upregulated by TIV and LAIV




Figure 5c. Accuracies of machine learning technique

Discussion: Limitations

- **Broad utility** still uncertain – gene signatures will vary for different vaccines
 - Overlapping genes with previous YF-17D study suggest some commonality across vaccines
- Predicting vaccine efficacy is not 100% accurate
 - **Immunogenicity ≠ Efficacy**
 - HAI response is not the only factor influencing vaccine protection
 - **Protective antibody concentrations vary** by individual, viral strain, etc.
 - Only workaround = increasing HAI parameter → excludes protected vaccinees with lower HAI responses


Discussion: Future steps

Improvements:

- Identify **other markers** for vaccine protection in conjunction with HAI response
- **Adapt the system** to other vaccines

Other applications:

- Monitoring **suboptimal immune responses** in weaker individuals
- **Personalized vaccinations** based on predictive modeling of individuals' immune systems



References

1. Querec, T. D., Rama Akondy, Lee, E. K., Cao, W., Helder Imoto Nakaya, Teuwen, D., Pirani, A., Gernert, K., Deng, J., Marzolf, B., Kennedy, K., Wu, H., Soumaya Bennouna, Herold Oluoch, Miller, J., Vencio, R. Z., Mulligan, M., Aderem, A., Ahmed, R., & Bali Pulendran. (2008). Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. *Nature Immunology*, 10(1), 116–125. <https://doi.org/10.1038/ni.1688>
2. Bali Pulendran. (2009). Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinology. *Nature Reviews. Immunology*, 9(10), 741–747. <https://doi.org/10.1038/nri2629>
3. Cowling, B. J., Wey Wen Lim, Perera, M., Fang, V. J., Leung, G. M., Peiris, M., & Tchetgen, E. J. (2018). Influenza Hemagglutination-inhibition Antibody Titer as a Mediator of Vaccine-induced Protection for Influenza B. *Clinical Infectious Diseases*, 68(10), 1713–1717. <https://doi.org/10.1093/cid/ciy759>
4. NCI Dictionary of Cancer Terms. (2024). Cancer.gov; Cancer.gov. <https://www.cancer.gov/publications/dictionaries/cancer-terms/def/seroconversion>
5. Poland, G. A., I.G. Ovsyannikova, & Kennedy, R. B. (2017). Personalized vaccinology: A review. *Vaccine*, 36(36), 5350–5357. <https://doi.org/10.1016/j.vaccine.2017.07.062>